Michael Quirmbach
Tracked across 3 events · 19 articles · First seen May 27, 2026 · Last active Sep 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
CordenPharma, a global pharmaceutical contract development and manufacturing organization (CDMO) backed by private equity firm Astorg, announced the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer effective 1 October 2026. Herbeaux succeeds Dr. Michael…
Impact: Quirmbach steps down as CEO after leading CordenPharma since 2019 and through 12 years of growth from 245 million euros to over 1 billion euros in revenue. He remains on the board and as Senior Advisor, preserving continuity.
Sep 15, 2026 · 6 articles
Business
Impact: As President & CEO of CordenPharma Group, Michael Quirmbach commented on the strategic importance of the acquisition for bolstering CordenPharma's Peptides Platform.
May 27, 2026 · 7 articles
Business
CordenPharma announced an acceleration of its sterile injectable CDMO manufacturing expansion at its FDA and EMA-approved Caponago site near Milan, Italy, anchored by a multi-year 80 million European Union — Euro investment program. As a…
Impact: As President and CEO of CordenPharma Group, Michael Quirmbach publicly framed the investment as strengthening leadership in complex-modality drug product manufacturing and end-to-end supply capabilities.
Sep 10, 2026 · 6 articles
70
Michael Quirmbach transitioned to board CordenPharmaCordenPharma CEO...
ERGEN INTELLIGENCE
Track Michael Quirmbach live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard